Catalent Appoints General ManagerBy
Catalent Pharma Solutions has appointed Marlene Leuenberger as General Manager of the company’s Drug Development Center of Excellence in Somerset, New Jersey.
Leuenberger has over 25 years’ management experience in engineering, quality operations, and plant management within the biotechnology and pharmaceutical industry. She joins Catalent from Impax Laboratories, a Hayward, California-based specialty pharmaceutical company, where she was General Manager and Senior Director of Operations for its Middlesex, New Jersey facility. Leuenberger has also held senior positions in operations at LTS Lohmann Therapy Systems Corp., Novartis Consumer Health, Wyeth (now Pfizer), and Procter & Gamble.
Catalent recently invested in the Somerset facility to create a new Drug Development Center of Excellence focused on preclinical to clinical Phase IIb formulation, analytical, and manufacturing solutions for orally delivered small molecules. In July 2018, the company also agreed to acquire Juniper Pharmaceuticals, including its Nottingham, UK-based Juniper Pharma Services division. The acquisition of Juniper will expand Catalent’s offerings in formulation development, bioavailability solutions, and clinical-scale oral dose manufacturing, and will add to its integrated global clinical and commercial supply network.
Catalent’s 265,000 square-foot headquarters and development center in Somerset houses analytical labs, pilot- and clinical-scale equipment, including hot-melt extrusion and fluid-bed processing, and the company has expertise in handling potent and US Drug Enforcement Administration compounds for capsules, tablets, minitablets, and multi-particulates.
Source: Catalent Pharma Solutions